title: Brimonidine gel (Mirvaso) for rosacea.
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D017277:Drug Approval; D005782:Gels; D006801:Humans; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012393:Rosacea / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D005782:Gels; D011810:Quinoxalines; D000068438:Brimonidine Tartrate